Tislelizumab by BeiGene for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval

Tislelizumab is under clinical development by BeiGene and currently in Pre-Registration for Esophageal Squamous Cell Carcinoma (ESCC).

Major Source of Lupus Morbidity More Common in Certain Racial-Ethnic Groups

Among patients with systemic lupus erythematosus (SLE), high titers of anti-phospholipid (aPL) antibodies were most prevalent in whites and Latinos and less so for Black

October 26, 2023

Galderma deprioritizes study for IL-31 drug; UCB stops work in rare encephalitis

Plus, news about GlycoMimetics and Indivior: Galderma stops plans to develop nemolizumab in Phase 2: The Swiss dermatology company said it … Sign up to

July 26, 2024

Sanofi adds another AI alliance, this time for biologics with Baidu CEO’s startup

Sanofi has teamed up on artificial intelligence once again. This time, it’s partnering with BioMap, a startup chaired by the CEO of Baidu, a Chinese

October 11, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.